论文部分内容阅读
目的观察葛根素对心源性脑梗死(cardiogenic cerebral embolism,CCE)患者的临床治疗效果。方法选择2013年2月—2016年3月CCE患者164例,将其随机分为对照组和观察组各82例,对照组采用常规治疗,观察组在常规治疗基础上给予葛根素葡萄糖注射液静脉滴注,两组均治疗14 d。分别于治疗前及治疗第1、3、5、7、14天采用神经功能缺损程度评分(national institute of health sroke scale,NIHSS)评价神经功能,统计总有效率,治疗前后采用Barthel指数评分对生活能力进行评估,记录治疗过程中的不良反应。计量资料比较采用t检验,计数资料比较采用χ2检验,P<0.05为差异有统计学意义。结果治疗后两组NIHSS均有所改善,治疗第1、3、5、7、14天对照组NIHSS分别为(22.8±7.4)、(22.7±6.8)、(21.9±6.2)、(19.4±6.0)、(16.2±7.1)分,观察组分别为(14.2±6.5)、(12.4±6.3)、(10.8±7.1)、(9.4±6.3)、(7.6±6.3)分,观察组NIHSS低于对照组,比较差异有统计学意义(均P<0.05)。对照组治疗总有效率(82.92%)低于观察组(95.12%),比较差异有统计学意义(P<0.05)。对照组治疗后Barthel指数评分[(61.5±14.6)分]高于治疗前[(31.0±10.4)分],观察组治疗后Barthel指数评分[(86.1±15.8)分]高于治疗前[(31.9±10.5)分],比较差异有统计学意义(均P<0.05);治疗后观察组Barthel指数评分明显高于对照组,比较差异有统计学意义(均P<0.05)。观察组有3例血压下降,1例出现面色潮红,5例出现胃肠道不适(如恶心呕吐等),减慢滴速后症状均消失,且均较轻微,未影响治疗。结论葛根素治疗CCE有显著的临床效果,可明显改善患者神经功能及生活质量。
Objective To observe the clinical effect of puerarin on patients with cardiogenic cerebral embolism (CCE). Methods A total of 164 CCE patients from February 2013 to March 2016 were selected and randomly divided into control group and observation group (n = 82). The control group was treated with conventional therapy. The observation group was given puerarin glucose intravenously Instillation, both groups were treated for 14 days. The neurological function was evaluated by National Institute of Health sroke scale (NIHSS) before treatment and on the 1st, 3rd, 5th, 7th and 14th day of treatment, respectively. The total effective rate was calculated. The Barthel index score Ability to assess and record adverse reactions during treatment. Measurement data were compared using t test, count data were compared using χ2 test, P <0.05 for the difference was statistically significant. Results NIHSS in both groups improved after treatment. The NIHSS in the control group on the 1st, 3rd, 5th, 7th and 14th day were (22.8 ± 7.4), (22.7 ± 6.8), (21.9 ± 6.2), (19.4 ± 6.0) ) And (16.2 ± 7.1) points in the observation group were (14.2 ± 6.5), (12.4 ± 6.3), (10.8 ± 7.1), (9.4 ± 6.3) and (7.6 ± 6.3) Group, the difference was statistically significant (all P <0.05). The total effective rate of the control group (82.92%) was lower than that of the observation group (95.12%), the difference was statistically significant (P <0.05). Barthel index score (61.5 ± 14.6) in control group was higher than that before treatment (31.0 ± 10.4), Barthel index score (86.1 ± 15.8) in observation group after treatment was higher than that before treatment (31.9 ± 10.5)], the difference was statistically significant (all P <0.05). After treatment, Barthel index score of the observation group was significantly higher than that of the control group (all P <0.05). In the observation group, there were 3 cases of decreased blood pressure, 1 case of flushing, 5 cases of gastrointestinal discomfort (such as nausea and vomiting), the symptoms disappeared after slowing down drip rate, and were mild, did not affect the treatment. Conclusion Puerarin treatment of CCE has a significant clinical effect, can significantly improve the patient’s neurological function and quality of life.